Pituitary somatostatin receptor signaling

Trends in Endocrinology and Metabolism

Volumn 21, Issue 3, 2010, Pages 123-133

  Ben Shlomo, Anat ^a   Melmed Shlomo, S ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ANGIOPEPTIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; G PROTEIN COUPLED RECEPTOR; ION CHANNEL; OCTREOTIDE; PASIREOTIDE; PHOSPHOPROTEIN PHOSPHATASE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

CALCIUM CELL LEVEL; CELL GROWTH; CHANNEL GATING; CORTICOTROPIN RELEASE; CUSHING DISEASE; DESENSITIZATION; DRUG TARGETING; GONADOTROPIN RELEASE; GROWTH INHIBITION; HORMONE ACTION; HUMAN; HYPOPHYSIS; HYPOTHALAMUS; INTERNALIZATION; PRIORITY JOURNAL; PROLACTIN RELEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; SOMATOSTATIN RELEASE; THYROTROPIN RELEASE;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; PITUITARY DISEASES; PITUITARY HORMONES; RECEPTORS, SOMATOSTATIN; SIGNAL TRANSDUCTION;

EID: 77949314882     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.12.003     Document Type: Review

References (143)

1. Patel Y.C. Somatostatin and its receptor family. Front Neuroendocrinol 1999, 20(3):157-198.
2. Reichlin S. Somatostatin. N Engl J Med 1983, 309(24):1495-1501.
3. Weckbecker G., et al. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2003, 2(12):999-1017.
4. Patel Y.C., Srikant C.B. Somatostatin mediation of adenohypophysial secretion. Annu Rev Physiol 1986, 48:551-567.
5. Mouhieddine O.E., et al. Growth hormone (GH)-releasing hormone tonically inhibits in vitro endogenous somatostatin in human GH-secreting tumors. J Clin Endocrinol Metab 1995, 80(5):1691-1695.
6. Ben-Shlomo A., Melmed S. Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 2008, 286(1-2):192-198.
7. Ben-Shlomo A., Melmed S. Pasireotide-a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs 2007, 10(12):885-895.
8. Fusco A., et al. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur J Endocrinol 2008, 158(5):595-603.
9. Ben-Shlomo A., et al. Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem 2005, 280(25):24011-24021.
10. van der Hoek J., et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 2005, 289(2):E278-E287.
11. Furth J., et al. ACTH secreting transplantable pituitary tumors. Proc Soc Exp Biol Med 1953, 84(1):253-254.
12. Tashjian A.H., et al. Establishment of clonal strains of rat pituitary tumor cells that secrete growth hormone. Endocrinology 1968, 82(2):342-352.
13. Bancroft F.C. Measurement of growth hormone synthesis by rat pituitary cells in culture. Endocrinology 1973, 92(4):1014-1021.
14. Devnath S., Inoue K. An insight to pituitary folliculo-stellate cells. J Neuroendocrinol 2008, 20(6):687-691.
15. Panetta R., Patel Y.C. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 1995, 56(5):333-342.
16. Reed D.K., et al. Pituitary somatostatin receptor (sst)1-5 expression during rat development: age-dependent expression of sst2. Endocrinology 1999, 140(10):4739-4744.
17. Zhang W.H., et al. Sexually dimorphic expression of sst1 and sst2 somatostatin receptor subtypes in the arcuate nucleus and anterior pituitary of adult rats. J Neuroendocrinol 1999, 11(2):129-136.
18. Cervia D., Bagnoli P. An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology. Pharmacol Ther 2007, 116(2):322-341.
19. Ren S.G., et al. Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 2003, 88(9):4239-4245.
20. Sharif N., et al. Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology 2007, 148(5):2095-2105.
21. Ben-Shlomo A., et al. Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. Mol Endocrinol 2007, 21(10):2565-2578.
22. Ben-Shlomo A., et al. Constitutive somatostatin receptor activity determines tonic pituitary cell response. Mol Endocrinol 2009, 23(3):337-348.
23. Tsaneva-Atanasova K., et al. Mechanism of spontaneous and receptor-controlled electrical activity in pituitary somatotrophs: experiments and theory. J Neurophysiol 2007, 98(1):131-144.
24. Spada A., et al. Inhibition of basal and corticotropin-releasing hormone-stimulated adenylate cyclase activity and cytosolic Ca2+ levels by somatostatin in human corticotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1990, 70(5):1262-1268.
25. Liu H.S., et al. Heterogeneity of the Ca2+ sensitivity of secretion in a pituitary gonadotrope cell line and its modulation by protein kinase C and Ca2+. J Cell Physiol 2006, 207(3):668-674.
26. Bonnefont X., et al. Rhythmic bursts of calcium transients in acute anterior pituitary slices. Endocrinology 2000, 141(3):868-875.
27. Bjøro T., et al. Vasoactive intestinal peptide and peptide with N-terminal histidine and C-terminal isoleucine increase prolactin secretion in cultured rat pituitary cells (GH4C1) via a cAMP-dependent mechanism which involves transient elevation of intracellular Ca2+. Mol Cell Endocrinol 1987, 49(2-3):119-128.
28. White R.E., et al. Potassium channel stimulation by natriuretic peptides through cGMP-dependent dephosphorylation. Nature 1993, 361(6409):263-266.
29. Yang S.K., Chen C. Involvement of somatostatin receptor subtypes in membrane ion channel modification by somatostatin in pituitary somatotropes. Clin Exp Pharmacol Physiol 2007, 34(12):1221-1227.
30. Yang S.K., et al. Somatostatin increases voltage-gated K+ currents in GH3 cells through activation of multiple somatostatin receptors. Endocrinology 2005, 146(11):4975-4984.
31. Takano K., et al. Different G proteins mediate somatostatin-induced inward rectifier K+ currents in murine brain and endocrine cells. J Physiol 1997, 502(Pt 3):559-567.
32. Chen C. G(o)2 and Gi3 proteins mediate the action of somatostatin on membrane Ca2+ and K+ currents in ovine pituitary somatotrophs. Clin Exp Pharmacol Physiol 1997, 24(8):639-645.
33. Degtiar V.E., et al. Receptors couple to L-type calcium channels via distinct Go proteins in rat neuroendocrine cell lines. J Physiol 1997, 502(Pt 2):321-333.
34. Kleuss C., et al. Different beta-subunits determine G-protein interaction with transmembrane receptors. Nature 1992, 358(6385):424-426.
35. Kleuss C., et al. Selectivity in signal transduction determined by gamma subunits of heterotrimeric G proteins. Science 1993, 259(5096):832-834.
36. Petrucci C., et al. Somatostatin-induced control of cytosolic free calcium in pituitary tumour cells. Br J Pharmacol 2000, 129(3):471-484.
37. Cervia D., et al. Inhibitory control of growth hormone secretion by somatostatin in rat pituitary GC cells: sst(2) but not sst(1) receptors are coupled to inhibition of single-cell intracellular free calcium concentrations. Neuroendocrinology 2002, 76(2):99-110.
38. Yang S.K., et al. Somatostatin decreases voltage-gated Ca2+ currents in GH3 cells through activation of somatostatin receptor 2. Am J Physiol Endocrinol Metab 2007, 292(6):E1863-E1870.
39. White R.E., et al. Somatostatin stimulates Ca(2+)-activated K+ channels through protein dephosphorylation. Nature 1991, 351(6327):570-573.
40. Kraicer J., Spence J.W. Release of growth hormone from purified somatotrophs: use of high K+ and the ionophore A23187 to elucidate interrelations among Ca++, adenosine 3′,5′-monophosphate, and somatostatin. Endocrinology 1981, 108(2):651-657.
41. Draznin B., et al. Exocytosis in normal anterior pituitary cells. Quantitative correlation between growth hormone release and the morphological features of exocytosis. J Clin Invest 1988, 81(4):1042-1050.
42. Holl R.W., et al. Spontaneous oscillations of intracellular calcium and growth hormone secretion. J Biol Chem 1988, 263(20):9682-9685.
43. Shimada O., et al. Morphological effects of somatostatin on rat somatotrophs previously activated by growth hormone-releasing factor. Cell Tissue Res 1990, 261(2):219-229.
44. Matsuno A., et al. Dynamics of subcellular organelles, growth hormone, Rab3B, SNAP-25, and syntaxin in rat pituitary cells caused by growth hormone releasing hormone and somatostatin. Microsc Res Tech 2003, 62(3):232-239.
45. Heisler S., et al. Somatostatin inhibits multireceptor stimulation of cyclic AMP formation and corticotropin secretion in mouse pituitary tumor cells. Proc Natl Acad Sci U S A 1982, 79(21):6502-6506.
46. Bilezikjian L.M., Vale W.W. Stimulation of adenosine 3′,5′-monophosphate production by growth hormone-releasing factor and its inhibition by somatostatin in anterior pituitary cells in vitro. Endocrinology 1983, 113(5):1726-1731.
47. Koch B.D., et al. Pertussis toxin blocks both cyclic AMP-mediated and cyclic AMP-independent actions of somatostatin. Evidence for coupling of Ni to decreases in intracellular free calcium. J Biol Chem 1985, 260(24):13138-13145.
48. Liu Y.F., et al. G protein specificity in receptor-effector coupling. Analysis of the roles of G0 and Gi2 in GH4C1 pituitary cells. J Biol Chem 1994, 269(19):13880-13886.
49. Tallent M., Reisine T. Gi alpha 1 selectively couples somatostatin receptors to adenylyl cyclase in pituitary-derived AtT-20 cells. Mol Pharmacol 1992, 41(3):452-455.
50. Tentler J.J., et al. Somatostatin acts by inhibiting the cyclic 3′,5′-adenosine monophosphate (cAMP)/protein kinase A pathway, cAMP response element-binding protein (CREB) phosphorylation, and CREB transcription potency. Mol Endocrinol 1997, 11(7):859-866.
51. Cervia D., et al. Biological activity of somatostatin receptors in GC rat tumour somatotrophs: evidence with sst1-sst5 receptor-selective nonpeptidyl agonists. Neuropharmacology 2003, 44(5):672-685.
52. Ramirez J.L., et al. Somatostatin stimulates GH secretion in two porcine somatotrope subpopulations through a cAMP-dependent pathway. Endocrinology 2002, 143(3):889-897.
53. Florio T. Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. Mol Cell Endocrinol 2008, 286(1-2):40-48.
54. Ikuyama S., et al. Phorbol ester and phospholipase C-induced growth hormone secretion from pituitary somatotroph adenoma cells in culture: effects of somatostatin, bromocriptine, and pertussis toxin. J Clin Endocrinol Metab 1987, 64(3):572-577.
55. Bocca L., et al. Nitric oxide biphasically modulates GH secretion in cultured cells of GH-secreting human pituitary adenomas. Minerva Endocrinol 2000, 25(3-4):55-59.
56. Luque R.M., et al. Differential contribution of nitric oxide and cGMP to the stimulatory effects of growth hormone-releasing hormone and low-concentration somatostatin on growth hormone release from somatotrophs. J Neuroendocrinol 2005, 17(9):577-582.
57. Vesely D.L. The interrelationship of somatostatin and guanylate cyclase activity. Mol Cell Biochem 1980, 32(3):131-134.
58. Judd A.M., et al. A possible role of arachidonate metabolism in the mechanism of prolactin release. Am J Physiol 1986, 250(3 Pt 1):E288-E295.
59. Cervia D., et al. Somatostatin (SRIF) modulates distinct signaling pathways in rat pituitary tumor cells; negative coupling of SRIF receptor subtypes 1 and 2 to arachidonic acid release. Naunyn Schmiedebergs Arch Pharmacol 2002, 365(3):200-209.
60. Hubina, E. et al. (2005) Novel molecular aspects of pituitary adenomas. J Endocrinol Invest 28 (11 Suppl International), 87-92.
61. Horiguchi K., et al. Transcriptional activation of the mixed lineage leukemia-p27Kip1 pathway by a somatostatin analogue. Clin Cancer Res 2009, 15(8):2620-2629.
62. Sarret P., et al. Receptor-mediated internalization is critical for the inhibition of the expression of growth hormone by somatostatin in the pituitary cell line AtT-20. J Biol Chem 1999, 274(27):19294-19300.
63. Hipkin R.W., et al. Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor. J Biol Chem 1997, 272(21):13869-13876.
64. Liu Q., et al. Site specificity of agonist and second messenger-activated kinases for somatostatin receptor subtype 2A (Sst2A) phosphorylation. Mol Pharmacol 2009, 76(1):68-80.
65. Peverelli E., et al. The third intracellular loop of the human somatostatin receptor 5 is crucial for arrestin binding and receptor internalization after somatostatin stimulation. Mol Endocrinol 2008, 22(3):676-688.
66. Ben-Shlomo A., Schmid H., Wawrowsky K., Pichurin O., Hubina E., Chesnokova V., Liu N.A., Culler M., Melmed S. Differential ligand-mediated pituitary somatostatin receptor subtype signalling: Implications for corticotroph tumor therapy. J Clin Endocrinol Metabol 2009, 94(11):4342-4350.
67. Reisine T., Axelrod J. Prolonged somatostatin pretreatment desensitizes somatostatin's inhibition of receptor-mediated release of adrenocorticotropin hormone and sensitizes adenylate cyclase. Endocrinology 1983, 113(2):811-813.
68. Presky D.H., Schonbrunn A. Somatostatin pretreatment increases the number of somatostatin receptors in GH4C1 pituitary cells and does not reduce cellular responsiveness to somatostatin. J Biol Chem 1988, 263(2):714-721.
69. Sugihara H., et al. Somatostatin reduces transcription of the growth hormone gene in rats. Endocrinology 1993, 132(3):1225-1229.
70. Tsukamoto N., et al. Octreotide treatment results in the inhibition of GH gene expression in the adenoma of the patients with acromegaly. Endocr J 1994, 41(4):437-444.
71. Acunzo J., et al. Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas. Cancer Res 2008, 68(24):10163-10170.
72. Simard J., et al. Regulation of growth hormone mRNA and pro-opiomelanocortin mRNA levels by cyclic AMP in rat anterior pituitary cells in culture. DNA 1986, 5(4):263-270.
73. Davis J.R., et al. Regulation of growth hormone secretion and messenger ribonucleic acid accumulation in human somatotropinoma cells in vitro. J Clin Endocrinol Metab 1989, 69(4):704-708.
74. Namba H., et al. Insulin-like growth factor-I action on growth hormone secretion and messenger ribonucleic acid levels: interaction with somatostatin. Endocrinology 1989, 124(4):1794-1799.
75. Tanner J.W., et al. Modulation of growth hormone (GH) secretion and GH mRNA levels by GH-releasing factor, somatostatin and secretagogues in cultured bovine adenohypophysial cells. J Endocrinol 1990, 125(1):109-115.
76. Gruszka A., et al. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology 2007, 148(12):6107-6114.
77. Colao A., et al. Medical therapy of pituitary adenomas: effects on tumor shrinkage. Rev Endocr Metab Disord 2009, 10(2):111-123.
78. Resmini E., et al. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 2007, 92(5):1592-1599.
79. Milosevic V., et al. Morphometric and functional changes of rat pituitary somatotropes and lactotropes after central administration of somatostatin. Pharmacology 1998, 57(1):28-34.
80. Lovren M., et al. Effects of somatostatins on gonadotrophic cells in female rats. Acta Histochem 1998, 100(3):329-335.
81. Milosevic V., et al. Effect of centrally administered somatostatin on pituitary thyrotropes in male rats. Histochem J 2000, 32(9):565-569.
82. Nolan L.A., et al. Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary. Endocrinology 2007, 148(6):2821-2827.
83. Low M.J., et al. Somatostatin is required for masculinization of growth hormone-regulated hepatic gene expression but not of somatic growth. J Clin Invest 2001, 107(12):1571-1580.
84. Luque R.M., et al. Use of the metallothionein promoter-human growth hormone-releasing hormone (GHRH) mouse to identify regulatory pathways that suppress pituitary somatotrope hyperplasia and adenoma formation due to GHRH-receptor hyperactivation. Endocrinology 2009, 150(7):3177-3185.
85. Brinkmeier M.L., et al. Thyroid hormone-responsive pituitary hyperplasia independent of somatostatin receptor 2. Mol Endocrinol 2001, 15(12):2129-2136.
86. Schussler N., et al. Effect of the slow-release formulation of somatuline (BIM 23014) on estrogen-induced hyperprolactinemia and lactotroph hyperplasia in the female rat. Neuropeptides 1994, 26(6):399-404.
87. Pawlikowski M., et al. The effect of somatostatin analog octreotide on diethylstilbestrol-induced prolactin secretion, cell proliferation and vascular changes in the rat anterior pituitary gland. Histol Histopathol 1997, 12(4):991-994.
88. Melmed S. Medical progress: Acromegaly. N Engl J Med 2006, 355(24):2558-2573.
89. Bevan J.S. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005, 90(3):1856-1863.
90. Melmed S., et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005, 90(7):4405-4410.
91. Lamberts S.W., et al. The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol (Copenh) 1989, 120(6):760-766.
92. Beck-Peccoz P., Persani L. Medical management of thyrotropin-secreting pituitary adenomas. Pituitary 2002, 5(2):83-88.
93. Ferrante E., et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer 2006, 13(3):955-962.
94. Florio T., et al. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol 1999, 141(4):396-408.
95. Batista D.L., et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 2006, 91(11):4482-4488.
96. Cap J., et al. The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas. J Clin Neurosci 2003, 10(4):444-448.
97. Cheung N.W., Boyages S.C. Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block. Endocrinology 1995, 136(10):4174-4181.
98. Giustina A., Veldhuis J.D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998, 19(6):717-797.
99. Farhy L.S., Veldhuis J.D. Putative GH pulse renewal: periventricular somatostatinergic control of an arcuate-nuclear somatostatin and GH-releasing hormone oscillator. Am J Physiol Regul Integr Comp Physiol 2004, 286(6):R1030-1042.
100. Luque R.M., et al. Role of endogenous somatostatin in regulating GH output under basal conditions and in response to metabolic extremes. Mol Cell Endocrinol 2008, 286(1-2):155-168.
101. Shimon I., et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 1997, 99(4):789-798.
102. Taboada G.F., et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 2008, 158(3):295-303.
103. Shimon I., et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997, 100(9):2386-2392.
104. Zatelli M.C., et al. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. J Clin Endocrinol Metab 2003, 88(6):2797-2802.
105. Schmid H.A. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008, 286(1-2):69-74.
106. Hofland L.J. Somatostatin and somatostatin receptors in Cushing's disease. Mol Cell Endocrinol 2008, 286(1-2):199-205.
107. Boscaro M., et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 2009, 94(1):115-122.
108. Samuels M.H., et al. Effects of dopamine and somatostatin on pulsatile pituitary glycoprotein secretion. J Clin Endocrinol Metab 1992, 74(1):217-222.
109. Jaquet P., et al. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 1999, 84(9):3268-3276.
110. Djordjijevic D., et al. Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures. Endocrinology 1998, 139(5):2272-2277.
111. Lee S.C., Shin S.H. Somatostatin does not inhibit prolactin synthesis in normal male rat pituitary cells but inhibits prolactin synthesis in estradiol-primed pituitary cells. J Endocrinol 1996, 148(1):69-76.
112. Goth M.I., et al. Chronic estrogen treatment in male rats reveals mammosomatotropes and allows inhibition of prolactin secretion by somatostatin. Endocrinology 1996, 137(1):274-280.
113. Gooren L.J., et al. Somatostatin inhibits prolactin release from the lactotroph primed with oestrogen and cyproterone acetate in man. J Endocrinol 1984, 103(3):333-335.
114. Klibanski A., et al. Somatostatin regulation of glycoprotein hormone and free subunit secretion in clinically nonfunctioning and somatotroph adenomas in vitro. J Clin Endocrinol Metab 1991, 73(6):1248-1255.
115. Spier A.D., de Lecea L. Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res Brain Res Rev 2000, 33(2-3):228-241.
116. Bruns C., et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002, 146(5):707-716.
117. Miller G.M., et al. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 1995, 80(4):1386-1392.
118. Schulz S., et al. Localization of five somatostatin receptors in the rat central nervous system using subtype-specific antibodies. J Physiol Paris 2000, 94(3-4):259-264.
119. Day R., et al. Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis. Endocrinology 1995, 136(11):5232-5235.
120. Mezey E., et al. Cell specific expression of the sst2A and sst5 somatostatin receptors in the rat anterior pituitary. Endocrinology 1998, 139(1):414-419.
121. Kumar U., et al. Expression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-layer immunofluorescence confocal microscopy. Endocrinology 1997, 138(10):4473-4476.
122. Takei M., et al. Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide. Endocr Pathol 2007, 18(4):208-216.
123. Park C., et al. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Endocr J 2004, 51(2):227-236.
124. Schaer J.C., et al. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 1997, 70(5):530-537.
125. Corbetta S., et al. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression. Eur J Clin Invest 2001, 31(3):208-214.
126. Greenman Y., Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 1994, 78(2):398-403.
127. Greenman Y., Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 1994, 79(3):724-729.
128. Murabe H., et al. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction. J Neuroendocrinol 1996, 8(8):605-610.
129. Hofland L.J., et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 2004, 89(4):1577-1585.
130. de Bruin C., et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab 2009, 94(4):1118-1124.
131. Hofland L.J., et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005, 152(4):645-654.
132. Pawlikowski M., et al. Immunohistochemical detection of somatostatin receptor subtypes in " clinically nonfunctioning" pituitary adenomas. Endocr Pathol 2003, 14(3):231-238.
133. Berelowitz M., et al. Regulation of somatostatin receptor mRNA expression. Ciba Found Symp 1995, 190:111-122. discussion 122-116.
134. Luque R.M., et al. Homologous and heterologous in vitro regulation of pig pituitary somatostatin receptor subtypes, sst1, sst2 and sst5 mRNA. J Mol Endocrinol 2004, 32(2):437-448.
135. Patel Y.C., et al. Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun 1993, 192(1):288-294.
136. Yan M., et al. Effect of GHRH and GHRP-2 treatment in vitro on GH secretion and levels of GH, pituitary transcription factor-1, GHRH-receptor, GH-secretagogue-receptor and somatostatin receptor mRNAs in ovine pituitary cells. Eur J Endocrinol 2004, 150(2):235-242.
137. Canosa L.F., et al. Effects of sex steroid hormones on the expression of somatostatin receptors sst1 and sst5 in goldfish pituitary and forebrain. Neuroendocrinology 2003, 78(2):81-89.
138. Cardenas R., et al. Estradiol reduces pituitary responsiveness to somatostatin (SRIF-14) and down-regulates the expression of somatostatin sst2 receptors in female goldfish pituitary. Gen Comp Endocrinol 2003, 132(1):119-124.
139. Kimura N., et al. Chronic treatment with estrogen up-regulates expression of sst2 messenger ribonucleic acid (mRNA) but down-regulates expression of sst5 mRNA in rat pituitaries. Endocrinology 1998, 139(4):1573-1580.
140. Xu Y., et al. Dexamethasone regulates somatostatin receptor subtype messenger ribonucleic acid expression in rat pituitary GH4C1 cells. Endocrinology 1995, 136(11):5070-5075.
141. James R.A., et al. Thyroid hormone-induced expression of specific somatostatin receptor subtypes correlates with involution of the TtT-97 murine thyrotrope tumor. Endocrinology 1997, 138(2):719-724.
142. Petersenn S., et al. Genomic structure and transcriptional regulation of the human somatostatin receptor type 2. Mol Cell Endocrinol 1999, 157(1-2):75-85.
143. Puente E., et al. Transcriptional activation of mouse sst2 somatostatin receptor promoter by transforming growth factor-beta. Involvement of Smad4. J Biol Chem 2001, 276(16):13461-13468.